MMP9 (matrix metallopeptidase 9) is a zinc-dependent endopeptidase that plays essential roles in extracellular matrix (ECM) remodeling and cellular processes 1. The enzyme degrades various ECM components including type IV and V collagens, cleaving them into characteristic three-quarter and one-quarter fragments, while also degrading fibronectin but sparing laminin [UniProt]. MMP9 facilitates cell migration and invasion by breaking down ECM barriers, with particular importance in leukocyte migration and trophoblast invasion during pregnancy 2. In cancer biology, MMP9 promotes tumor progression through ECM remodeling that enhances invasiveness and activates cancer-associated fibroblasts 3. The enzyme contributes to inflammatory processes, with elevated levels observed in periodontal disease where it serves as a sensitive biomarker 1. MMP9 is implicated in cardiovascular pathology, participating in vascular remodeling during intracranial aneurysm formation through ROS-mediated pathways 4 and contributing to atherosclerosis development 5. Clinical significance includes its potential as a diagnostic biomarker for pancreatic cancer, particularly in advanced stages 6, and its role in transplant rejection through M2 macrophage polarization 7. Genetic polymorphisms in MMP9 are associated with increased breast cancer risk in certain populations 8.